Publications
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | First Faculty of Medicine
- Escalating therapy in multiple sclerosis2012 | First Faculty of Medicine
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?2011 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient?2011 | First Faculty of Medicine
- Risks of Immune System Treatments2010 | First Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | First Faculty of Medicine
- Freedom from disease activity in multiple sclerosis2010 | First Faculty of Medicine
Loading network view...